Two Sigma Advisers’s Unity Biotechnology UBX Stock Holding History

Two Sigma Advisers’s Portfolio UBX Stock Details UBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-20,940	Closed	-$118K	–	2736
2022 Q2	$118K	Sell	20,940 -12,650	-38%	-$106K	﹤0.01%	2371
2022 Q1	$376K	Sell	33,590 -18,680	-36%	-$210K	﹤0.01%	2123
2021 Q4	$763K	Buy	52,270 +36,750	+237%	+$803K	﹤0.01%	1707
2021 Q3	$466K	Buy	15,520 +9,950	+179%	+$351K	﹤0.01%	1953
2021 Q2	$258K	Sell	5,570 -1,070	-16%	-$51.5K	﹤0.01%	2187
2021 Q1	$398K	Buy	+6,640	New	+$453K	﹤0.01%	2105

Other funds holding UBX

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Empery Asset Management New York $83M AUM

ACM

Altium Capital Management New York $42M AUM

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Two Sigma Advisers's UBX Position: Q3 2022 in Review

Two Sigma Advisers sold out of Unity Biotechnology (UBX) in Q3 2022, closing a stake of 20,940 shares — an estimated $118K sold.

Two Sigma Advisers first reported a position in UBX in Q1 2021 and held it in 6 quarters. The position peaked at $763K in Q4 2021. 72 funds tracked by Wall St. Rank hold UBX as of Q3 2022.

Two Sigma Advisers reported no remaining Unity Biotechnology position as of Q3 2022 after selling out during the quarter.
Two Sigma Advisers sold 20,940 Unity Biotechnology shares in Q3 2022, an estimated $118K.
Two Sigma Advisers first reported a position in Unity Biotechnology in Q1 2021 and held it in 6 quarters.
Two Sigma Advisers's Unity Biotechnology position peaked at $763K in Q4 2021.
72 funds tracked by Wall St. Rank held Unity Biotechnology as of Q3 2022.

Based on Two Sigma Advisers's 13F filing for Q3 2022, filed 14 Nov 2022.